Remember, it was in early October, Donald Trump, positive for Covid-19, was hospitalized at Walter Reed Hospital, on the outskirts of Washington. This is where the former president of the United States had turned to a particular treatment. Donald Trump had received the antiviral remdesivir as well as a dose of the experimental cocktail. synthetic antibodies developed by the Regeneron company.
A treatment tested at that time in only 275 people. Whether or not this treatment resulted, the former head of state was discharged from the hospital a few days later. A month later, at the end of November, this treatment with Regeneron’s synthetic antibodies was authorized in the United States by the United States Agency for Medicines (FDA).
According to Reuters, cited by Western france, the European Medicines Agency (EMA) gave this Friday, a favorable opinion for this treatment, “to treat Covid-19 patients who do not require oxygen supply and pose high risks to reach a serious stage of the disease, “says Reuters.
Last October, Donald Trump’s doctors had also explained when administering this treatment, that the president did not “need additional oxygen”.
Similar treatment already authorized in France
In France, Olivier Véran explained this Thursday, February 25, that a new synthetic antibody drug has just been authorized for patients with a higher risk of suffering from severe forms, in the hope of avoiding hospitalization and resuscitation. “They are new hopes … that strengthen our anti-Covid arsenal,” said the Minister of Health. It is that of the American laboratory Eli Lilly which is currently authorized in France.
“Some 83 hospitals have already received thousands of this treatment that can be started with caution initially in a hospital setting for patients aged 80 years and over, and who have immune disorders,” added Olivier Véran.